Arrowhead Pharma (ARWR) Stock Up 481% in a Year — Analysts Say There's More to Come
21 Apr 2026 · 16:12 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
Arrowhead Pharmaceuticals (ARWR) stock has gained 481% over the past year. Morgan Stanley upgraded ARWR to Overweight with a $100 price target, up from $78. The company is developing plozasiran to treat severe hypertriglyceridemia, with Phase 3 trial data expected in Q3 2026. Bank of America also raised its price target. Analysts model peak sales of approximately $3.2 billion for plozasiran, suggesting significant upside potential from current valuations.
Why it matters
Arrowhead Pharmaceuticals operates in the traditional healthcare sector. Their Phase 3 trial results for plozasiran and analyst price targets reflect equity market fundamentals specific to the pharmaceutical industry, with zero relevance to digital asset valuations. While broad macroeconomic conditions can influence risk appetite across asset classes, this specific company news is too narrow and unrelated to create measurable crypto market impact. The article's publication on CoinCentral (a cryptocurrency news platform) appears to be editorial misplacement or content farming, suggesting lower quality control at the source and reducing credibility for crypto-focused readers.
Expected impact
This article concerns Arrowhead Pharmaceuticals (ARWR), a traditional pharmaceutical company unrelated to cryptocurrency or blockchain. The analyst upgrades and drug development milestones have no direct connection to crypto markets. Pharmaceutical sector performance does not meaningfully influence Bitcoin or altcoin valuations across any timeframe. Any indirect impact through broad risk-sentiment channels would be negligible and heavily diluted by numerous competing market factors. Crypto markets primarily respond to crypto-native catalysts (regulatory announcements, protocol developments, exchange dynamics) rather than biotech equity news.